Table of Contents
JERUSALEM — Teva Pharmaceutical Industries Ltd. has received approval from the Food and Drug Administration for tobramycin inhalation solution in the United States.
Teva said Monday that its product is a generic equivalent of Novartis’ TOBI, an aminoglycoside antibiotic.
Pursuant to an agreement with Novartis, Teva expects to launch its product in late November.
Marketed by Novartis, TOBI had annual sales of approximately $350 million in the United States, according to IMS Health data as of June 30, Teva reported.
